Vivek Subbiah, Rare Cancers
Vivek Subbiah/LinkedIn

Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn by Conquer Cancer, the ASCO Foundation, adding:

“Rare cancers deserve breakthroughs too

Less funding = fewer lifesaving discoveries.

American Society of Clinical Oncology (ASCO), Conquer Cancer, the ASCO Foundation support research for every cancer, no matter how rare.

Your gift fuels hope for every patient, everywhere.”

Quoting Conquer Cancer, the ASCO Foundation’s post:

“While a single rare cancer might affect a small number of patients, rare cancers – as a whole – actually make up about 1 out of every 4 new cancer diagnoses and an estimated 25 percent of all cancer deaths every year. Here’s what you need to know about rare cancers and how you can help conquer them.”

Proceed to the video attached to the post.

More posts featuring Vivek Subbiah.